BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 11331074)

  • 1. Resistance of human multidrug resistance-associated protein 1-overexpressing lung tumor cells to the anticancer drug arsenic trioxide.
    Vernhet L; Allain N; Payen L; Anger JP; Guillouzo A; Fardel O
    Biochem Pharmacol; 2001 Jun; 61(11):1387-91. PubMed ID: 11331074
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Differential sensitivities of MRP1-overexpressing lung tumor cells to cytotoxic metals.
    Vernhet L; Allain N; Bardiau C; Anger JP; Fardel O
    Toxicology; 2000 Jan; 142(2):127-34. PubMed ID: 10685512
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Overexpression of the multidrug resistance-associated protein (MRP1) in human heavy metal-selected tumor cells.
    Vernhet L; Courtois A; Allain N; Payen L; Anger JP; Guillouzo A; Fardel O
    FEBS Lett; 1999 Jan; 443(3):321-5. PubMed ID: 10025956
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The sulphonylurea glibenclamide inhibits multidrug resistance protein (MRP1) activity in human lung cancer cells.
    Payen L; Delugin L; Courtois A; Trinquart Y; Guillouzo A; Fardel O
    Br J Pharmacol; 2001 Feb; 132(3):778-84. PubMed ID: 11159731
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The MRP1-mediated effluxes of arsenic and antimony do not require arsenic-glutathione and antimony-glutathione complex formation.
    Salerno M; Petroutsa M; Garnier-Suillerot A
    J Bioenerg Biomembr; 2002 Apr; 34(2):135-45. PubMed ID: 12018890
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Establishment of an arsenic trioxide-resistant human leukemia cell line that shows multidrug resistance.
    Seo T; Urasaki Y; Ueda T
    Int J Hematol; 2007 Jan; 85(1):26-31. PubMed ID: 17261498
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Arsenic trioxide sensitivity is associated with low level of glutathione in cancer cells.
    Yang CH; Kuo ML; Chen JC; Chen YC
    Br J Cancer; 1999 Nov; 81(5):796-9. PubMed ID: 10555748
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Differential expression and response to arsenic stress of MRPs and ASAN1 determine sensitivity of classical multidrug-resistant leukemia cells to arsenic trioxide.
    Chen J; Cheng J; Yi J; Xie B; Lin L; Liu Z; Zhao H; Wang B; Ai Z; Yang Y; Wei H
    Leuk Res; 2016 Nov; 50():116-122. PubMed ID: 27736728
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Arsenic trioxide circumvents multidrug resistance based on different mechanisms in human leukemia cell lines.
    Seo T; Urasaki Y; Takemura H; Ueda T
    Anticancer Res; 2005; 25(2A):991-8. PubMed ID: 15868938
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Blockage of multidrug resistance-associated proteins potentiates the inhibitory effects of arsenic trioxide on CYP1A1 induction by polycyclic aromatic hydrocarbons.
    Vernhet L; Allain N; Le Vée M; Morel F; Guillouzo A; Fardel O
    J Pharmacol Exp Ther; 2003 Jan; 304(1):145-55. PubMed ID: 12490585
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Use of the anionic dye carboxy-2',7'-dichlorofluorescein for sensitive flow cytometric detection of multidrug resistance-associated protein activity.
    Laupeze B; Amiot L; Courtois A; Vernhet L; Drenou B; Fauchet R; Fardel O
    Int J Oncol; 1999 Sep; 15(3):571-6. PubMed ID: 10427142
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effective treatment of advanced solid tumors by the combination of arsenic trioxide and L-buthionine-sulfoximine.
    Maeda H; Hori S; Ohizumi H; Segawa T; Kakehi Y; Ogawa O; Kakizuka A
    Cell Death Differ; 2004 Jul; 11(7):737-46. PubMed ID: 15002036
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Resistance to mitoxantrone in multidrug-resistant MCF7 breast cancer cells: evaluation of mitoxantrone transport and the role of multidrug resistance protein family proteins.
    Diah SK; Smitherman PK; Aldridge J; Volk EL; Schneider E; Townsend AJ; Morrow CS
    Cancer Res; 2001 Jul; 61(14):5461-7. PubMed ID: 11454692
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Regulation of ABCG2 by nuclear factor kappa B affects the sensitivity of human lung adenocarcinoma A549 cells to arsenic trioxide.
    Jiang X; Chen C; Gu S; Zhang Z
    Environ Toxicol Pharmacol; 2018 Jan; 57():141-150. PubMed ID: 29274627
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of arsenic trioxide (As2O3) on leukemic cells from patients with non-M3 acute myelogenous leukemia: studies of cytotoxicity, apoptosis and the pattern of resistance.
    Lehmann S; Bengtzen S; Paul A; Christensson B; Paul C
    Eur J Haematol; 2001 Jun; 66(6):357-64. PubMed ID: 11488934
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Arsenic trioxide combined with buthionine sulfoximine enhances apoptosis in multidrug-resistant human leukemia K562/ADM cells in vitro].
    Wang T; Ma LM; Zhang HP; Wang HW; Yang LH; Qiao ZH
    Zhonghua Zhong Liu Za Zhi; 2008 Mar; 30(3):188-91. PubMed ID: 18756933
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Reversal of MRP-mediated multidrug resistance in human lung cancer cells by the antiprogestatin drug RU486.
    Payen L; Delugin L; Courtois A; Trinquart Y; Guillouzo A; Fardel O
    Biochem Biophys Res Commun; 1999 May; 258(3):513-8. PubMed ID: 10329417
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Kinetics of glutathione and daunorubicin efflux from multidrug resistance protein overexpressing small-cell lung cancer cells.
    Salerno M; Garnier-Suillerot A
    Eur J Pharmacol; 2001 Jun; 421(1):1-9. PubMed ID: 11408043
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Overexpression of glutathione S-transferase II and multidrug resistance transport proteins is associated with acquired tolerance to inorganic arsenic.
    Liu J; Chen H; Miller DS; Saavedra JE; Keefer LK; Johnson DR; Klaassen CD; Waalkes MP
    Mol Pharmacol; 2001 Aug; 60(2):302-9. PubMed ID: 11455017
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Multidrug-resistant tumor cells remain sensitive to a recombinant interleukin-4-Pseudomonas exotoxin, except when overexpressing the multidrug resistance protein MRP1.
    de Jong MC; Scheffer GL; Broxterman HJ; Hooijberg JH; Slootstra JW; Meloen RH; Kreitman RJ; Husain SR; Joshi BH; Puri RK; Scheper RJ
    Clin Cancer Res; 2003 Oct; 9(13):5009-17. PubMed ID: 14581376
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.